CO2017012974A2 - Anticuerpos de unión a tau - Google Patents

Anticuerpos de unión a tau

Info

Publication number
CO2017012974A2
CO2017012974A2 CONC2017/0012974A CO2017012974A CO2017012974A2 CO 2017012974 A2 CO2017012974 A2 CO 2017012974A2 CO 2017012974 A CO2017012974 A CO 2017012974A CO 2017012974 A2 CO2017012974 A2 CO 2017012974A2
Authority
CO
Colombia
Prior art keywords
binding antibodies
tau binding
tau
antibodies
tauopathies
Prior art date
Application number
CONC2017/0012974A
Other languages
English (en)
Inventor
David Edward Ormonde Knight
Georges Mairet-Coello
Patrick Downey
Jean-Philippe Courade
Kerry Louise Tyson
Terence Seward Baker
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of CO2017012974A2 publication Critical patent/CO2017012974A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a anticuerpos de unión a Tau y fragmentos de unión de los mismos, métodos para hacer dicho anticuerpo y el uso de los mismos para el tratamiento y/o el diagnóstico de tauopatías tales como la enfermedad de Alzheimer (AD) y la supranuclear progresiva (PSP).
CONC2017/0012974A 2015-07-06 2017-12-18 Anticuerpos de unión a tau CO2017012974A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15175519 2015-07-06
PCT/EP2016/065809 WO2017005732A1 (en) 2015-07-06 2016-07-05 Tau-binding antibodies

Publications (1)

Publication Number Publication Date
CO2017012974A2 true CO2017012974A2 (es) 2018-03-09

Family

ID=53524638

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0012974A CO2017012974A2 (es) 2015-07-06 2017-12-18 Anticuerpos de unión a tau

Country Status (23)

Country Link
US (4) US10344081B2 (es)
EP (1) EP3319984A1 (es)
JP (1) JP6937289B2 (es)
KR (1) KR20180027566A (es)
CN (1) CN107849105B (es)
AR (1) AR105266A1 (es)
AU (1) AU2016289753C1 (es)
BR (1) BR112017028101A2 (es)
CA (1) CA2991264C (es)
CL (1) CL2018000042A1 (es)
CO (1) CO2017012974A2 (es)
EA (1) EA036821B1 (es)
EC (1) ECSP18000844A (es)
IL (1) IL256687B (es)
MA (2) MA41669A1 (es)
MX (1) MX2017015908A (es)
PE (1) PE20180499A1 (es)
PH (1) PH12017502180A1 (es)
TN (1) TN2017000543A1 (es)
TW (1) TWI748954B (es)
UY (1) UY36774A (es)
WO (1) WO2017005732A1 (es)
ZA (1) ZA201708128B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24446B1 (es) 2013-03-13 2019-10-04 Prothena Biosciences Ltd Un anticuerpo monoclonal humanizado que se une a tau
MX2017015464A (es) 2015-06-05 2018-03-28 Genentech Inc Anticuerpos anti-tau y metodos de uso.
KR20180027566A (ko) 2015-07-06 2018-03-14 유씨비 바이오파마 에스피알엘 타우 결합 항체
MA42377A (fr) 2015-07-06 2018-05-16 Ucb Biopharma Sprl Anticorps se liant à tau
EP3452508A1 (en) 2016-05-02 2019-03-13 Prothena Biosciences Limited Antibodies recognizing tau
JP7170316B2 (ja) 2016-05-02 2022-11-14 プロセナ バイオサイエンシーズ リミテッド タウ免疫療法
KR20230146126A (ko) 2016-12-07 2023-10-18 제넨테크, 인크. 항-타우 항체 및 이의 이용 방법
JP2020511937A (ja) 2016-12-07 2020-04-23 ジェネンテック， インコーポレイテッド 抗ｔａｕ抗体及び使用方法
WO2018148447A1 (en) * 2017-02-08 2018-08-16 Adimab, Llc Antibody heavy chain variable domains targeting the nkg2d receptor
CA3221995A1 (en) 2017-02-08 2018-08-16 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
CA3053379A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
US11884732B2 (en) 2017-02-20 2024-01-30 Dragonfly Therapeutics, Inc. Proteins binding HER2, NKG2D and CD16
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
SG11201910066QA (en) 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
MX2020003857A (es) 2017-10-16 2021-01-08 Eisai R&D Man Co Ltd Anticuerpos anti-tau y uso de los mismos.
JP2021512630A (ja) 2018-02-08 2021-05-20 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ受容体を標的とする抗体可変ドメイン
EP3894438A1 (en) * 2018-12-13 2021-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) New anti tau svqivykpv epitope single domain antibody
WO2020180819A1 (en) 2019-03-03 2020-09-10 Prothena Biosciences Limited Antibodies recognizing tau
AU2021251486A1 (en) * 2020-04-08 2022-12-08 Janssen Biotech, Inc. Anti-PHF-TAU antibodies and uses thereof
MX2022016322A (es) 2020-06-25 2023-01-24 Merck Sharp & Dohme Llc Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413.
WO2022144406A1 (en) * 2020-12-29 2022-07-07 Neurimmune Ag Human anti-tau antibodies
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
WO1993008302A1 (en) 1991-10-25 1993-04-29 Itt Automotive Europe Gmbh Monoclonal antibodies directed against the microtubule-associated protein tau
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
US6010913A (en) 1992-12-14 2000-01-04 N.V. Innogenetics S.A. Isolated human tau peptide
CA2178212C (en) 1993-12-21 2011-06-14 Marc Vandermeeren Monoclonal antibodies specific for phf-tau, hybridomas secreting them, antigen recognition by these antibodies and their applications
US6121003A (en) 1994-07-29 2000-09-19 Innogentics N.V. Monoclonal antibodies specific for an epitope of phosphorylated tau, and their use
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
WO2005003169A2 (en) 2003-07-01 2005-01-13 Celltech R & D Limited Modified antibody fab fragments
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
CN1721437A (zh) * 2004-07-13 2006-01-18 中南大学 一种与Tau蛋白相关的多肽抗原及抗体
CN101370525B (zh) 2005-08-19 2013-09-18 Abbvie公司 双重可变结构域免疫球蛋白及其用途
KR20150098683A (ko) 2005-12-12 2015-08-28 에이씨 이뮨 에스.에이. 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
JP5592792B2 (ja) 2007-09-26 2014-09-17 ユセベ ファルマ ソシエテ アノニム 二重特異性抗体の融合体
CN103992405B (zh) * 2008-03-26 2016-08-17 宜康公司 抗-vegf抗体
CN101307108B (zh) * 2008-06-25 2012-04-04 南京川博生物技术有限公司 抗磷酸化Tau蛋白抗体及其在AD症异常磷酸化Tau蛋白水平测定上的用途
WO2010035012A1 (en) 2008-09-26 2010-04-01 Ucb Pharma S.A. Biological products
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
JP5917394B2 (ja) 2009-06-10 2016-05-11 ニューヨーク・ユニバーシティ 病理学的タウタンパク質の免疫学的標的化方法
KR20130127547A (ko) 2009-07-30 2013-11-22 화이자 백신스 엘엘씨 항원성 타우 펩타이드 및 이의 용도
US20120283415A1 (en) 2009-09-10 2012-11-08 Ucb Pharma S.A. Multivalent Antibodies
CA2813493C (en) 2010-10-11 2019-07-09 University Of Zurich Human anti-tau antibodies
US8703137B2 (en) 2011-01-31 2014-04-22 Intellect Neurosciences Inc. Treatment of tauopathies
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
CN109265543B (zh) 2011-09-19 2022-04-26 阿克松神经系统科学公司 阿尔茨海默病中的tau蛋白介导病变的基于蛋白质的疗法和诊断
US9803004B2 (en) 2011-11-11 2017-10-31 Ucb Biopharma Sprl Albumin binding antibodies and binding fragments thereof
EA027975B1 (ru) 2011-12-20 2017-09-29 Янссен Байотек, Инк. Анти-псф-тау-антитела и их применение
CN104520322B (zh) 2012-04-05 2019-11-15 Ac免疫有限公司 人源化tau抗体
CA2877397A1 (en) 2012-07-03 2014-01-09 Washington University Antibodies to tau
WO2014016737A1 (en) 2012-07-24 2014-01-30 Pfizer Inc. Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof
MY176838A (en) * 2012-08-16 2020-08-24 Ipierian Inc Methods of treating a tauopathy
LT2935326T (lt) 2012-12-21 2020-12-10 Biogen Ma Inc. Žmogaus antikūnai prieš tau baltymą
CU24446B1 (es) 2013-03-13 2019-10-04 Prothena Biosciences Ltd Un anticuerpo monoclonal humanizado que se une a tau
KR102233349B1 (ko) 2013-03-15 2021-03-31 에이씨 이뮨 에스.에이. 항-타우(tau) 항체 및 사용 방법
MX2016007208A (es) 2013-12-20 2016-07-21 Hoffmann La Roche Anticuerpos anti-tau(ps422) humanizados y metodos de uso.
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
TWI669314B (zh) 2015-02-26 2019-08-21 美國禮來大藥廠 針對ｔａｕ之抗體及其用途
MX2017015464A (es) 2015-06-05 2018-03-28 Genentech Inc Anticuerpos anti-tau y metodos de uso.
KR20180027566A (ko) 2015-07-06 2018-03-14 유씨비 바이오파마 에스피알엘 타우 결합 항체
MA42377A (fr) 2015-07-06 2018-05-16 Ucb Biopharma Sprl Anticorps se liant à tau
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها

Also Published As

Publication number Publication date
US10906966B2 (en) 2021-02-02
AR105266A1 (es) 2017-09-20
BR112017028101A2 (pt) 2018-09-04
JP2018519833A (ja) 2018-07-26
PH12017502180A1 (en) 2018-05-28
EA036821B1 (ru) 2020-12-23
US10344081B2 (en) 2019-07-09
US20190375829A1 (en) 2019-12-12
US11746145B2 (en) 2023-09-05
US20210139574A1 (en) 2021-05-13
TN2017000543A1 (en) 2019-04-12
IL256687B (en) 2022-02-01
ZA201708128B (en) 2019-05-29
JP6937289B2 (ja) 2021-09-22
CA2991264A1 (en) 2017-01-12
EP3319984A1 (en) 2018-05-16
CL2018000042A1 (es) 2018-06-01
MA41669A1 (fr) 2018-05-31
AU2016289753A1 (en) 2017-12-14
US20230331833A1 (en) 2023-10-19
TW201713688A (zh) 2017-04-16
AU2016289753B2 (en) 2020-11-26
WO2017005732A1 (en) 2017-01-12
MX2017015908A (es) 2018-03-15
EA201890169A1 (ru) 2018-10-31
TWI748954B (zh) 2021-12-11
ECSP18000844A (es) 2018-03-31
MA42380A (fr) 2018-05-16
UY36774A (es) 2017-01-31
AU2016289753C1 (en) 2021-08-05
CN107849105B (zh) 2021-09-17
KR20180027566A (ko) 2018-03-14
PE20180499A1 (es) 2018-03-09
US20180194832A1 (en) 2018-07-12
CN107849105A (zh) 2018-03-27
CA2991264C (en) 2023-10-10
IL256687A (en) 2018-03-29

Similar Documents

Publication Publication Date Title
CO2017012974A2 (es) Anticuerpos de unión a tau
CO2017012971A2 (es) Anticuerpos de unión a tau
CL2019001735A1 (es) Anticuerpos monoclonales anti-alfa-sinucleína para prevenir la agregación de tau.
CL2018001971A1 (es) Ror1 composiciones de anticuerpos y métodos relacionados
CL2017000310A1 (es) Anticuerpos anti tigit
EA201791485A1 (ru) Анти-cd47-антитела и их применения
CY1122265T1 (el) Αντισωματα εναντι ταυ και χρησεις αυτων
EA202092435A3 (ru) Моноклональные антитела против bcma
DOP2018000281A (es) Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso
GT201700131A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
TW201613962A (en) Fabs-in-tandem immunoglobulin and uses thereof
BR112016014731A2 (pt) Anticorpos anti-baff
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
EA201891299A1 (ru) Терапевтические антитела к cd9
WO2016057683A3 (en) Novel anti-nodal antibodies and methods of using same
BR112018008900A8 (pt) composições compreendendo anticorpos para il6r para o tratamento de uveíte e edema macular e métodos de uso das mesmas
UY36262A (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
CO2019013718A2 (es) Anticuerpos anti-trkb
AR120118A2 (es) Anticuerpos anti tigit
CR20190012A (es) Anticuerpos específicos para la tauy hiperfosforilada y sus métodos de uso
EA201892257A1 (ru) Анти-cd3 антитела и способы применения